___

• Aday L.A. et al. (1993) Evaluating the Medical Care System: Effectiveness, Efficiency, and Equity. Health Administration Press, University of Michigan (Ann Arbor, MI). 2.
• Ades A.E., Claxton K. and Sculpher M. (2006) Evidence Synthesis, Parameter Correlation and Probabilistic Sensitivity Analysis. Health Economics 15(4): 373-381. 3.
• Ades A.E. and Cliffe S. (2002) Markov chain Monte Carlo estimation of a multiparameter decision model: consistency of evidence and the accurate assessment of uncertainty. Medical Decision Making 22: 359– 371. 4.
• Anderson J.P. et al. (1986) Policy space areas and properties of benefit- cost/utility analysis. JAMA 255: 794-795. 5.
• Arrow K.J. (1963) Uncertainty and the Welfare Economics of Medical Care. American Economic Review 53(3): 941–973. 6.
• Black W.C. (1990) The CE Plane: A Graphic Representation of Cost- Effectiveness. Medical Decision Making 10: 212-214.
• Boadway R. and Bruce N. (1984) Welfare Economics. Oxford: Basil Blackwell.
• Briggs A. and Fenn P. (1998) Confidence Intervals or Surfaces? Uncertainty on the Cost-Effectiveness Plane. Health Economics 7: 723- Brook R. and Lohr K. (1985) Efficacy, Effectiveness, Variations, and Quality: Boundary-Crossing Research. Medical care 23(suppl.): 710- 722.
• Claxton K., Sculpher M., McCabe C. et al. (2005) Probabilistic Sensitivity Analysis for NICE Technology Assessment: Not An Optional Extra. Health Economics 14: 339–347.
• Coast J. (2004) Is economic evaluation in touch with society's health values? British Medical Journal 329: 1233-1236.
• Cookson R. et al. (2001) Worng SIGN, NICE Mess: Is National Guidance Distorting Allocation of Resources? British Medical Journal 323: 743-745.
• Diel R., Nienhaus A. and Loddenkempe R. (2007) Cost-effectiveness of Interferon-Release Assay Screening for Latent Tuberculosis Infection Treatment in Germany. CHEST 131:1424–1434.
• Doubilet P., Begg C.B., Weinstein M.C., Braun P. and McNeil B.J. (1985) Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Medical Decision Making5(2): 157-177
• Drummond M.F. et al. (2006) Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press Inc., New York.
• Drummond M.F. (2003) The Use of Economic Information by Reimbursement Authorities. Rheumatology 42(Supply. 3): iii60-iii63.
• Drummond M.F., Aguiar-Ibáñez, R. and Nixon, J. (2006) Economic Evaluation. Singapore Medical Journal 47(6): 456-462.
• Ebri A., Kuper H. and Wedner S. (2007) Cost-Effectiveness of Cycloplegic Agents: Results of a Randomized Controlled Trial in Nigerian Children. Investigative Ophthalmology & Visual Science 48(3): 1025-1031.
• Elliott R. and Payne K. (2005) Essentials of Economic Evaluation in Health Care. Pharmaceutical Press, London.
• Folland S. et al. (1997) The Economics of Health and Health Care. New Jersey: Prentice Hall.
• Gafni A. and Birch S. (2006) Incremental Cost-effectiveness ratios (ICERs): The Silence of the Lambda. Social Science and Medicine 62: 2091-2100.
• Gage H. et al. (2006) Evaluating rehabilitation using cost-consequences analysis: an example in Parkinson's disease. Clinical Rehabilitation 20: 232-238.
• Groot KB. et al. (2007). Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis. Medical Decision Making 27: 101-111.
• Hutubessy R. et al. (2003) Generalized Cost-Effectiveness Analysis for National-level Priority-setting in the Health Sector. Cost Effectiveness and Resource Allocation 1: 8-20.
• Jacobs R. et al. (2006) Measuring Efficiency in Health Care. Cambridge University Press, UK.
• James M. et al. (2005) A Cost Consequences Analysis of Local Corticosteroid Injection and Physiotherapy for the Treatment of New Episodes of Unilateral Shoulder Pain in Primary Care. Rheumatology 44(11):1447-1451.
• Lipscomb J., Weinstein M.C. and Torrance G.W. (1996) “Time Preference”. In Gold M.R., Siegel J.E., Russell L.B. and Weinstein M.C. (eds.) Cost Effectiveness in Health and Medicine, pp:214-246. Oxford University Press.
• Liu et al. (2005) Health Care and Pharmaceutical Spending in Turkey. SUVAK, Ankara. (www.suvak.org.tr)
• Lord J. and Asante M.A. (1999) Estimating Uncertainty Ranges for Costs by the Bootstrap Procedure Combined with Probabilistic Sensitivity Analysis. Health Economics 8: 323–333.
• Mandelblatt J.S. et al. (1996) “Assessing the Effectiveness of Health Interventions”. In Gold M.R., Siegel J.E., Russell L.B. and Weinstein M.C. (eds.) Cost Effectiveness in Health and Medicine, pp:135-175. Oxford University Press.
• Manning W.G., Fryback D.G. and Weinstein M.C. (1996) “Time Preference”. In Gold M.R., Siegel J.E., Russell L.B. and Weinstein M.C. (eds.) Cost Effectiveness in Health and Medicine, pp:214-246. Oxford University Press.
• Meltzer M.I. (2001) Introduction to Health Economics for Physicians. Lancet 358: 993–998.
• Multicentre Aneurysm Screening Study (MASS) (2002) Cost effectiveness analysis of screening for abdominal aortic aneurysms based on four year results from randomised controlled trial. British Medical Journal 325:1135.
• Murray C.J.L. et al. (2000) Development of WHO Guidelines on Generalized Cost-effectiveness Analysis. Health Economics 9: 235-251. Mushkin S.J. (1958) Toward A Definition of Health Economics. Public Health Reports 73(9): 785- 793.
• Mushkin S.J. (1962) Health as an Investment. Journal of Political Economy 70(5): 129-157.
• Plant P.K., Owen J.L., Parrott S. and Elliott M.W. (2003) Cost Effectiveness of Ward Based Non-Invasive Ventilation for Acute Exacerbations of Chronic Obstructive Pulmonary Disease: Economic Analysis of Randomised Controlled Trial. British Medical Journal 326: Robertson J. et al. (2003) Use of Pharmacoeconomics in Prescribing Research. Part 1: Costs – Moving Beyond the Acquisition Price for Drugs. Journal of Clinical Pharmacy and Therapeutics 28: 73–79.
• Samuelson P.A. and Nordhaus W.D. (1995) Micro Economics. McGraw- Hill, Inc.
• Sendi P.P. and Briggs A.H. (2001) Affordability and Cost-Effectiveness: Decision-making on the Cost-Effectiveness Plane. Health Economics 10: 675-680.
• Sendi P., Gafni A. and Birch S. (2002) Opportunity Costs and Uncertainty in the Economic Evaluation of Health Care Interventions. Health Economics 11: 23-31.
• Stinnett A.A. and Mullahy J. (1998) Net Health Benefits: A New Framework for the Analysis of Uncertainty in Cost-Effectiveness Analysis. Medical Decision Making 18(2 Suppl): S68-80.
• Suraratdecha C., Ramana C.B.S.V., Kaipilyawar S., Krishnamurthy J.V.G., Sivalenka S., Ambatipudi N., Gandhi S., Umashankar K. & Cheyne J. (2008) Cost and effectiveness analysis of immunization service delivery support in Andhra Pradesh, India. Bulletin of the World Health
• (http://www.ncbi.nlm.nih.gov) (Erişim Tarihi 13 Haziran 2008) 86. Elektronik
• Sürüm Tan-Torres Edejer T. et al. (2003) Making Choices in Health Care: WHO Guide to Cost-Effectiveness Analysis. World Health Organization, Geneva.
• Tatar M. (2007) Pharmaprofile. Turkey. Pharmaceutical Pricing and Reimbursement Information (PPRI) (www.ppri.oebig.at).
• Van Hout B. et al. (1994) Costs, Effects and C/E Ratios Alongside A Clinical Trial. Health Economics 3: 309-319.
• Wake N. et al. (2000) Cost-Effectiveness of Intensive Insulin Therapy for Type 2 Diabetes: A 10-Year Follow-up of the Kumamoto Study. Diabetes Research and Clinical Practice 48(3): 201-210.
• Walley T. (2004) Pharmacoeconomics and Economic Evaluation of Drug Therapies. In du Souich P. et al. (eds.) The IUPHAR Compendium of Basic Principles for Pharmacological Research in Humans, pp:67-75. Department of Pharmacology College of Medicine, University of California, USA.
• WHO (2007) An Overview of the Rationale, Activities and Goals of WHO-CHOICE, http://www.who.int/choice/description/importance/en, 27.08.2007.